Returns | 1W : -8% , 1M : -8.8%,1Y : 242.7% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
KOPRAN LTD | -8% | -8.8% | 242.7% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -1.6% | -0.6% | 27.8% |
DR REDDYS LABORATORIES LTD | -0.1% | -2.3% | 65.7% |
DIVIS LABORATORIES LTD | -0.9% | -4.8% | 86.8% |
CIPLA LTD | 1.8% | 0.4% | 73.9% |
BIOCON LTD | -15.3% | -20.6% | 33.9% |
AUROBINDO PHARMA LTD | 8% | 9.8% | 88.7% |
LUPIN LTD | -0.8% | 10.8% | 46.3% |
TORRENT PHARMACEUTICALS LTD | -4.2% | -5.3% | 33.1% |
Ratio | Value |
---|---|
P/E P/B P/S |
24.39
P/E Calculated based on EPS of 4.86
[ Mar2020 - Consolidated Results ] 2.7
P/B Calculated based on Book Value of 43.86
[ Mar2020 - Consolidated Results ] 1.3
P/S Calculated based on Revenues of 396.233 Cr
[ TTM - Consolidated Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
60% 60% 123% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |